Comprehensive notes on monoclonal antibodies: structure, diversity, production, CDR grafting, and clinical implications

Immunoglobulin Structure

• Immunoglobulin (Ig) molecule composed of two identical heavy chains and two identical light chains forming a Y-shaped molecule.
• Structural domains:
  • Variable regions: VL (variable domain of light chain) and VH (variable domain of heavy chain)
  • Constant regions: CL (constant domain of light chain) and CH (constant domain of heavy chain)
• Heavy chain constant domains: CH1, CH2, CH3 (and CH4 in IgM/IgA not shown here; focus on CH2/CH3 for effector functions)
• Light chain constant domain: CL
• Antigen-binding site formed by the variable domains of heavy and light chains (VH and VL) together with CDRs embedded in those domains
• Disulfide bonds linking heavy and light chains: S-S bonds stabilize structure
• Regions and motifs noted on Page 3:
  • Variable domain of heavy chain (V_H)
  • Variable domain of light chain (V_L)
  • Complementarity determining regions (CDRs) within VH and VL
  • CDR-H1, CDR-H2, CDR-H3 in VH; CDR-L1, CDR-L2, CDR-L3 in VL
  • Antibody segments: Fab (antigen-binding fragment) and Fc (crystallizable fragment); Fv denotes the variable regions of both heavy and light chains
• Diagrammatic cues:
  • Antibody consists of two Fab arms and one Fc stem
  • The hinge regions and disulfide linkages geometry antibody structure for antigen contact and effector function
• Practical relevance:
  • The combination of VH and VL variability plus CDR diversity underlies antigen recognition breadth
  • Structural organization enables generation of diverse antibody repertoires while maintaining a conserved scaffold for effector functions

CDR: Complementarity Determining Regions

• CDR stands for Complementarity Determining Regions, the hypervariable loops that contact antigen
• In each chain there are three CDRs:
  • Heavy chain: CDR-H1, CDR-H2, CDR-H3
  • Light chain: CDR-L1, CDR-L2, CDR-L3
• Fv denotes the antigen-binding fragment formed by the variable regions of heavy and light chains; Fab is the fragment containing Fab arms; Fc is the constant region responsible for effector functions
• Organization noted in Page 4:
  • VH paired with CH1, VL paired with CL, and the CDRs embedded within VH and VL
• Significance:
  • Diversity and specificity of antigen binding are primarily determined by the CDRs, especially CDR-H3 which often contributes most to antigen contact

How does a human produce antibodies against nearly unlimited pathogen types?

• Core challenge: enormous antigenic diversity from countless pathogens
• Key strategies the immune system employs:
  • Germline diversity: a large, diverse set of V, D, and J gene segments for BCRs (B cell receptors) and TCRs
  • Somatic diversification: during B cell development, receptor genes undergo recombination and mutation to create receptor variants
  • Clonal selection: B and T cells bearing receptors with higher affinity for the encountered antigen are selected to proliferate
• Result: a polyclonal response initially; affinity-matured clones expand to produce high-affinity antibodies
• Foundational concepts linked to later monoclonal antibody technology

Clonal Selection Theory and evolution within the body

• Central idea: lymphocytes bearing receptors that weakly recognize foreign antigens are stimulated; this leads to diversification and selection for higher affinity
• Figure 5.1 (described):
  • Antigen binding to surface receptors on T and B cells initiates stimulation
  • Receptor genes undergo further diversification during activation
  • Cells with weak binding are eliminated; cells with high-affinity receptors proliferate
  • Resulting cells differentiate into antibody-producing cells (B cells becoming plasma cells)
• Key processes:
  • Variant generation within receptor genes (diversity arises through recombination and mutation)
  • Clonal expansion of high-affinity B cells
• Conceptual takeaway: adaptive immunity is an iterative, selective process sculpting receptor repertoires toward strong antigen recognition

From Fabrication to Production: B cell maturation and antibody production

• Figure 5.2 describes the maturation pathway:
  • Naïve B cells display membrane-bound B cell receptors (BCRs) with variant structures hardcoded in the genome
  • Upon antigen binding, signals trigger genetic diversification and clonal expansion
  • The clone undergoes selection for progressively tighter binding to the antigen (affinity maturation)
  • Differentiation culminates in plasma cells that secrete soluble antibody (secreted form) and memory B cells for future responses
• Distinct fates:
  • Plasmablasts → Plasma cells (secrete soluble antibody)
  • Memory B cells (long-lived, rapidly differentiate into plasma cells upon re-exposure)
• Distinction between membrane-bound receptors and soluble antibodies
• Note: Panel A adapted from Upasani et al. (2021); emphasizes maturation and diversification with a transition from membrane-bound to soluble antibodies

Foundation of variant generation within the immune cells: germline inheritance

• Each person inherits two sets of BCR loci and two sets of TCR loci (diploidy for both BCR and TCR loci)
• Estimated segment counts per parent:
  • BCR V segments: about 45
  • TCR V segments: about 40
• Total potential combinatorial diversity (illustrative calculation):
  • $Total = 45 \times 2 \times 40 \times 2 = 7{,}200$
• Implication:
  • Even before somatic diversification, the germline repertoire provides substantial diversity to seed adaptive responses

VDJ recombination and somatic diversification

• The immune system further diversifies via somatic DNA processes during lymphocyte development
• Key concepts:
  • VDJ recombination provides diversity in the heavy chain by joining one V, one D, and one J segment
  • Light chains undergo VJ recombination (no D segment)
  • Recombination Signal Sequences (RSS) guide the rearrangement in two steps (two-step recombination for heavy chains; one step for light chains)
• Mechanistic notes (Panel B, Page 9):
  • Components involved: V, D, J gene segments; RSSs flank these segments
  • P nucleotide additions and N nucleotide additions contribute to junctional diversity
  • Heavy chain rearranges V-D-J; light chain rearranges V-J
  • Transcriptional regulation involves a promoter (P) and enhancer (E) of transcription for proper expression
• Result:
  • A vast combinatorial and junctional diversity in Ig genes, creating a broad receptor repertoire before antigen exposure

Investigating the immune challenge: how many pathogens and proteins are known?

• Questions posed:
  • How many different pathogenic bacteria and viruses exist for humans?
  • How many different foreign proteins are known today?
  • What is the minimum requirement for the variable chain CDR region to detect every protein as foreign and elicit an antibody response?
• Implication:
  • These questions highlight the limits of natural diversity and the motivation for developing monoclonal antibodies and targeted therapies

Cellular events for selecting antibodies (antigen presentation and B/T cell collaboration)

• Key players in antigen recognition and selection:
  • Antigen-presenting cells (APCs): Dendritic cells presenting via MHC molecules
  • B cells and T cells: activation requires T cell help, antigen recognition, and costimulatory signals
  • Major histocompatibility complex (MHC) molecules:
  • MHC I presents to CD8+ T cells; involved in cytotoxic responses and NK cell recognition
  • MHC II presents to CD4+ T helper cells; crucial for B cell activation and antibody production
• Pathway sketch (Page 11):
  • Dendritic cell takes up antigen and presents peptides on MHC I/II
  • T cells interact with MHC-peptide complexes on APCs
  • B cells internalize antigen, present peptides on MHC II to helper T cells
  • Helper T cell signals promote B cell activation, class switching, and affinity maturation
• Outcome: coordinated cellular events lead to high-affinity antibody production by B cells

Polyclonal vs monoclonal antibodies

• A single antigen can induce multiple antibodies (polyclonal response) within an organism
• Polyclonal antibodies considerations:
  • Not all have high specificity
  • Not all bind strongly
  • Not all neutralize the pathogen
• For therapeutic purposes, a single high-quality antibody is preferred (monoclonal antibody)
• Implication for therapy development: isolation and production of a uniform, high-affinity antibody is advantageous for consistent clinical outcomes

Pipeline for monoclonal antibodies (Discussion 2: 10-minute flow and analysis)

• Schematic workflow (Page 14):
  • Mouse challenged with antigen → Spleen cells collected
  • Fusion with myeloma cells to create hybridomas
  • Culture in HAT medium to select for hybrids
  • Harvest monoclonal antibodies from positive hybrids
• Step-by-step with advantages/disadvantages:
  • Mouse challenge with antigen
  • Advantage: elicits a targeted immune response; yields antigen-specific B cells
  • Disadvantage: potential immunogenicity in humans if mouse-derived
  • Fusion of spleen cells with myeloma cells (hybridomas)
  • Advantage: immortal cell lines producing a single antibody
  • Disadvantage: may require optimization for efficient fusion
  • HAT medium selection
  • Advantage: selectively supports hybridomas (unfused myeloma cells die due to aminopterin blocking DNA synthesis)
  • Disadvantage: may be slow; some positive clones may be lost
  • Positive clone screening and antibody harvesting
  • Advantage: yields stable monoclonal antibodies with defined specificity
  • Disadvantage: downstream human compatibility issues if murine antibodies are used
• Practical goal: obtain monoclonal antibodies with well-defined specificity and production stability

Hypoxanthine-Aminopterin-Thymidine (HAT) medium

• Purpose: selective medium to allow growth of only hybridomas after fusion
• Mechanism:
  • Aminopterin inhibits folate metabolism, blocking de novo DNA synthesis
  • Hypoxanthine and Thymidine provide DNA synthesis material via salvage pathways
  • Requires hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and thymidine kinase (TK) to utilize salvage pathways
• Summary reaction logic:
  • In unfused myeloma cells, Aminopterin blocks DNA synthesis; these cells die
  • In unfused spleen cells (non-immortal), they have limited lifespan; they die
  • In fused hybrids (hybridomas), salvage pathways allow DNA synthesis using provided hypoxanthine and thymidine, enabling growth
• Teaching takeaway:
  • HAT medium enriches for successfully fused hybridoma cells capable of producing monoclonal antibody

Discussion 3: Planning monoclonal antibodies in the 1980s – immunogenicity and clinic adoption

• Problem: patients react negatively with human anti-mouse antibody (HAMA) responses to mouse-derived antibodies
• Cross-disciplinary options considered:
  • Immunologist: address immunogenicity and human compatibility
  • Molecular biologist: engineering solutions to reduce immunogenicity (chimeric/humanized antibodies)
  • Clinician: ensure patient safety and therapeutic efficacy
  • Pharma executive: scaling production and ensuring profitability
• Core strategic question:
  • How can mouse-derived antibodies be made more compatible with humans to reduce adverse immune responses while preserving efficacy?

Why graft only the CDRs and not the entire variable region? (Jones et al.)

• Question: Why did Jones et al. graft only the CDRs and not the entire variable region?
• Rationale:
  • The CDRs contain the key antigen-contacting residues; grafting these onto human antibody frameworks can preserve antigen specificity while replacing the murine framework with human sequences to reduce immunogenicity
  • Preserves human constant regions to improve compatibility and effector functions in humans

How did they perform the CDR grafting? (Page 18)

• Process described (simplified):
  • Mouse protein sequence: identify CDR1, CDR2, CDR3 regions in mouse antibodies
  • Corresponding DNA sequences for these CDRs are identified
  • Human constant region DNA sequences (C_H) are prepared
  • Contiguous DNA sequences encoding mouse CDRs are synthesized and attached to human C_H DNA in vitro
  • The resulting chimeric DNA is introduced into mouse myeloma/B cell hybridomas to produce antibody with human constant regions and mouse CDRs
• Goal: create antibodies with human effector regions and murine antigen-binding sites, reducing immunogenicity while retaining specificity

Jones et al. results: interpretation of grafting outcomes

• Original mouse antibody binds the hapten NP-cap and NIP-cap
• Grafted hybrid antibody demonstrated binding to the antigen with equivalent specificity to the original mouse antibody
• Conclusion: CDR grafting can preserve binding specificity while converting the antibody into a human-compatible format for therapeutic use

Conclusions and open questions (Page 20)

• Takeaways:
  • Hybrid antibodies combining murine CDRs with human constant regions can retain antigen specificity while improving human compatibility
  • The grafting approach represents a foundational strategy in the development of therapeutic monoclonal antibodies
• Open questions discussed:
  • How broadly can CDR grafting be applied across different antigens and antibody frameworks?
  • What are the long-term immunogenicity and efficacy implications of various grafting strategies (chimeric, humanized, fully human) in patients?

Next class and readings (Module overview)

• Preparation:
  • Read the review paper K: “Strategies and challenges for the next generation of therapeutic antibodies”
  • Module 3: Gene Targeting; Read L: “Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene” (Thomas & Capecchi)
• Activities:
  • Write reflections on paper K for the next class

Connections, implications, and broader context

• Real-world relevance:
  • Monoclonal antibodies revolutionized therapeutics, enabling targeted treatment for cancers, autoimmune diseases, and infectious diseases
  • Early work on grafting CDRs laid groundwork for modern humanized and fully human antibodies
• Ethical and practical implications:
  • Immunogenicity concerns necessitated engineering approaches to improve patient safety
  • Balancing efficacy, safety, and cost remains a central challenge in therapeutic antibody development
• Foundational principles linked to broader immunology:
  • Clonal selection, affinity maturation, and the balance between diversity and specificity
  • Germline-encoded diversity complemented by somatic diversification to meet antigenic challenges
• Notable notes from the slides:
  • The immune system relies on both polyclonal responses (breadth) and monoclonal strategies (precision) to tackle diverse pathogens
  • The HAT medium is a classic technique enabling selective growth of hybridomas by exploiting nucleotide salvage pathways
  • CDR grafting represents an early, pivotal strategy toward human-compatible antibodies, addressing immunogenicity without sacrificing function

Summary of key formulas and numeric references

• Germline diversity estimate:
  • $Total = 45 \times 2 \times 40 \times 2 = 7{,}200$
• HAT medium mechanism (conceptual, not a numeric formula):
  • Aminopterin blocks de novo DNA synthesis; salvage pathway enabled by Hypoxanthine and Thymidine; TK is required to convert to TMP
• Core concepts to remember:
  • CDRs determine antigen contact; grafting aims to preserve specificity while replacing murine frameworks
  • Hybridomas enable immortal production of monoclonal antibodies
  • Immunogenicity considerations drive engineering toward humanized and fully human antibodies